High plasma pentosidine level is accompanied with cardiovascular events in hemodialysis patients

Clinical and Experimental Nephrology

Volumn 16, Issue 3, 2012, Pages 421-426

  Furuya, Ryuichi ^a   Kumagai, Hiromichi ^b   Miyata, Toshio ^c   Fukasawa, Hirotaka ^a   Isobe, Shinsuke ^a   Kinoshita, Naoko ^a   Hishida, Akira ^d  

^a Iwata City Hospital   (Japan)

^b UNIVERSITY OF SHIZUOKA   (Japan)

^c TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^d University of Tokyo   (Japan)

Author keywords

Cardiovascular event; Hemodialysis; Pentosidine

Indexed keywords

ADVANCED GLYCATION END PRODUCT; PENTOSIDINE;

ADULT; AGED; ARTICLE; BLOOD LEVEL; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; HEMODIALYSIS PATIENT; HIGH RISK PATIENT; HUMAN; HUMAN CELL; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; PENTOSIDINE BLOOD LEVEL; PREDICTION; PROSPECTIVE STUDY; STROKE;

AGED; ARGININE; C-REACTIVE PROTEIN; CARDIOVASCULAR DISEASES; FEMALE; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; KAPLAN-MEIER ESTIMATE; KIDNEY FAILURE, CHRONIC; LYSINE; MALE; MIDDLE AGED; PROGNOSIS; RENAL DIALYSIS; RISK;

EID: 84863728067     PISSN: 13421751     EISSN: 14377799     Source Type: Journal    
DOI: 10.1007/s10157-011-0573-3     Document Type: Article

References (30)

1. Sakata N, Imanaga Y, Meng J, Tachikawa Y, Takebayashi S, Nagai R, et al. Increased advanced glycation end products in atherosclerotic lesions of patients with end-stage renal disease. Atherosclerosis. 1999;142:67-77.
2. Suliman ME, Stenvinkel P, Jogestrand T, Maruyama Y, Qureshi AR, Barany P, et al. Plasma pentosidine and total homocysteine levels in relation to change in common carotid intima-media area in first year of dialysis therapy. Clin Nephrol. 2006;66:418-25.
3. Ueno H, Koyama H, Fukumoto S, Tanaka S, Shoji T, Shoji T, et al. Advanced glycation end products, carotid atherosclerosis, and circulating endothelial progenitor cells in patients with endstage renal disease. Metabolism. 2011;60:453-9.
4. Taki K, Takayama F, Tsuruta Y, Niwa T. Oxidative stress, advanced glycation end products and coronary artery calcification in hemodialysis patients. Kidney Int. 2006;70:218-24.
5. Koyama Y, Takeishi Y, Arimoto T, Niizeki T, Shishido T, Takahashi H, et al. High serum level of pentosidine, an advanced glycation end products (AGE), is a risk factor for patients with heart failure. J Cardiac Fail. 2007;13:199-206.
6. Nin JW, Jorsal A, Ferreira I, Schalkwijk CG, Prins MH, Parving HH, et al. Higher plasma levels of advanced glycation end products are associated with incident cardiovascular disease and all-cause mortality in type 1 diabetes. A 12-year follow-up study. Diabetes Care. 2011;34:442-7.
7. Stein G, Busch M, Muller A, Wendt T, Franke C, Niwa T, et al. Are advanced glycation end products cardiovascular risk factors in patients with CRF? Am J Kidney Dis. 2003;41(S1):S52-6.
8. Miyata T, Wada Y, Cai Z, Iida Y, Horie K, Yasuda Y, et al. Implication of an increased oxidative stress in the formation of advanced glycation end products in patients with end stage renal failure. Kidney Int. 1997;51:1170-81.
9. Descamps-Latscha B, Witko-Sarsat V, Nguyen-Khoa T, Nguyen AT, Gausson V, Mothu N, et al. Advanced oxidation protein products as risk factors for atherosclerotic cardiovascular events in nondiabetic predialysis patients. Am J Kidney Dis. 2004;45: 39-47.
10. Miyata T, Kurokawa K, de Strihou C. Advanced glycation and lipoxidation end products: Role of reactive carbonyl compounds generated during carbohydrate and lipid metabolism. J Am Soc Nephrol. 2000;11:1744-52.
11. Miyata T, Ueda Y, Yamada Y, Izuhara Y, Wada T, Jadoul M, et al. Accumulation of carbonyls accelerates the formation of pentosidine, an advanced glycation end products: Carbonyl stress in uremia. J Am Soc Nephrol. 1998;9:2349-56.
12. Meerwaldt R, Hartog JWL, Graaff R, Huisman RJ, Links TP, den Hollander NC, et al. Skin autofluorescence, a measure of cumulative metabolic stress and advanced glycation end products, predicts mortality in hemodialysis patients. J Am Soc Nephrol. 2005;16:3687-93.
13. Wagner Z, Molnar M, Molnar GA, Tamasko M, Laczy B, Wagner L, et al. Serum carboxymethyllysine predicts mortality in hemodialysis patients. Am J Kidney Dis. 2005;47:294-300.
14. Roberts MA, Thomas MC, Fernando D, Macmillan N, Power DA, Ierino FL. Low molecular weight advanced glycation end products predict mortality in asymptomatic patients receiving chronic haemodialysis. Nephrol Dial Transplant. 2006;21: 1611-7.
15. Miyata T, Ueda Y, Shinzato T, Iida Y, Tanaka S, Kurokawa K, et al. Accumulation of albumin-linked and free-form pentosidine in the circulation of uremic patients with end-stage renal failure: renal implications in the pathophysiology of pentosidine. J Am Soc Nephrol. 1996;7:1198-206.
16. London GM, Guerin AP, Marchais SJ, Metivier F, Pannier B, Adda H. Arterial media calcification in end-stage renal disease: Impact on all-cause and cardiovascular mortality. Nephrol Dial Transplant. 2003;18:1731-40.
17. Sakata N, Noma A, Yamamoto Y, Okamoto K, Meng J, Takebayashi S, et al. Modification of elastin by pentosidine is associated with the calcification of aortic media in patients with end-stage renal disease. Nephrol Dial Transplant. 2003;18:1601-9.
18. Kitauchi T, Yoshida K, Yoneda T, Saka T, Yoshikawa M, Ozono S, et al. Association between pentosidine and arteriosclerosis in patients receiving hemodialysis. Clin Exp Nephrol. 2004;8: 48-53.
19. Schwedler SB, Metzger T, Schinzel R, Wanner C. Advanced glycation end products and mortality in hemodialysis patients. Kidney Int. 2002;62:301-10.
20. Sozio S, Armstrong PA, Coresh J, Jaar BG, Fink NE, Plantinga L, et al. Cerebrovascular disease incidence, characteristics, and outcomes in patients initiating dialysis: The choices for healthy outcomes in caring for ESRD (CHOICE) study. Am J Kidney Dis. 2009;54:468-77.
21. Ohnuki Y, Nagano R, Takizawa S, Takagi S, Miyata T. Advanced glycation end products in patients with cerebral infarction. Intern Med. 2009;48:587-91.
22. Ikeda T, Maruyama K, Ito N, Utagawa A, Nagane M, Shiokawa Y. Serum pentosidine, an advanced glycation end product, indicates poor outcomes after acute ischemic stroke. J Stroke Cerebrovasc Dis. 2010 [Epub ahead of print].
23. Bush M, Franke S, Muller A, Wolf M, Gerth J, Ott U, et al. Potential cardiovascular risk factors in chronic kidney disease: AGEs, total homocysteine and metabolites, and the C-reactive protein. Kidney Int. 2004;66:338-47.
24. Miyata T, Ishiguro N, Yasuda Y, Ito T, Nangaku M, Iwata H, et al. Increased pentosidine, an advanced glycation end product, in plasma and synovial fluid from patients with rheumatoid arthritis and its relation with inflammation markers. Biochem Biophys Res Commun. 1988;244:45-9.
25. Suliman ME, Heimburger O, Barany P, Anderstam B, Pecoits-Filho R, Ayala ER, et al. Plasma pentosidine is associated with inflammation and malnutrition in end-stage renal disease patients starting on dialysis therapy. J Am Soc Nephrol. 2003;14:1614-22.
26. Jadoul M, Ueda Y, Yasuda Y, Saito A, Robert A, Ishida N, et al. Influence of hemodialysis membrane type on pentosidine plasma level, a marker of "carbonyl stress". Kidney Int. 1999;55:2478-92.
27. Furuya R, Kumagai H, Takahashi M, Sano K, Hishida A. Ultrapure dialysate reduces plasma levels of b2-microglobulin and pentosidine in hemodialysis patients. Blood Purif. 2005;23:311-6.
28. Gerdemann A, Wagner Z, Solf A, Bahner U, Heidland A, Vienken J, et al. Plasma levels of advanced glycation end products during haemodialysis, haemodiafiltration and haemofiltration: Potential importance of dialysate quality. Nephrol Dial Transplant. 2002;17:1045-9.
29. Miyata T, de Strihou C, Ueda Y, Ichimori K, Inagi R, Onogi H, et al. Angiotensin II receptor antagonists and angiotensin converting enzyme inhibitors lower in vitro the formation of advanced glycation end products: biochemical mechanisms. J Am Soc Nephrol. 2002;13:2478-87.
30. Makita Z, Radoff S, Rayfield EJ, Yang Z, Skolnik E, Delaney V, et al. Advanced glycosylation end products in patients with diabetic nephropathy. N Engl J Med. 1991;325:836-42.